Abbvie Stock Earnings Reports

AbbVie reported a strong Q1 2026 with adjusted EPS of $2.65 (above guidance midpoint) and total net revenues of $15.0 billion, up 12.4% year-over-year. Management raised full-year adjusted EPS guidance to $14.08–$14.28 and increased revenue guidance to about $67.3 billion, reflecting continued momentum across core franchises. Commercial highlights: Skyrizi and Rinvoq both outperformed expectations (Skyrizi $4.5B, +29% operational; Rinvoq $2.1B, +20%), with Skyrizi gaining share in psoriatic disease and IBD and strong new data supporting expanded use (including subcutaneous induction for Crohn's). Neuroscience and Parkinson’s products (Vraylar, VYALEV, upcoming tavapadon) continue to grow. Oncology momentum includes Venclexta growth and pipeline expansion via deals (e.g., PD-1/VEGF bispecific). R&D progress: multiple regulatory submissions and promising pipeline readouts anticipated in 2026 — notably Skyrizi subcutaneous induction for Crohn’s, Rinvoq for alopecia areata, interim data showing the Skyrizi + anti–alpha4beta7 (ABBV-382) combination doubling endoscopic remission in refractory Crohn’s, positive early obesity (ABBV-295) weight‑loss data, and several oncology acceleration plans. Financials: adjusted gross margin ~83.6% in Q1, adjusted operating margin guidance around mid-40s% (full year ~47.5%); capital allocation remains focused on R&D and manufacturing investments (announced $1.4B NC campus and $380M in North Chicago), business development, and dividends. Management emphasized strong cash/financial capacity for further BD to bolster immunology, neuroscience, oncology, and obesity pipelines.